AmerisourceBergen to buy PharMEDium Healthcare Holdings for US$2.6bn
Broadening its supplies of outsourced compounded sterile preparations to hospitals
AmerisourceBergen plans to purchase US drug compounding firm PharMEDium Healthcare Holdings from private equity company Clayton, Dubilier & Rice.
Under the deal, the global pharmaceutical sourcing and distribution services company will pay US$2.6bn for the supplier of outsourced compounded sterile preparations (CSPs) to acute care hospitals in the US.
The transaction is expected to close by 31 December and PharMEDium will become part of AmerisourceBergen Drug Corporation.
'The acquisition of PharMEDium strengthens our core business and meaningfully expands our innovative service offerings for health systems,” said Steven Collis, AmerisourceBergen President and Chief Executive.
'PharMEDium is a compelling addition to our business, which allows us to provide differentiated offerings and further increases our ability to drive both value and efficiency for our health systems customers in a way that enhances patient safety and helps improve patient outcomes.'
PharMEDium delivers “sterile to sterile” CSPs in a ready to use form with enhanced safety, labelling, sterility assurance, and extended expiration dating. The CSPs are prepared in state-of-the-art, FDA and state board of pharmacy inspected facilities, using only FDA-approved or allowed drugs in finished dosage form and FDA-approved diluents and FDA-cleared containers.
The firm maintains four compounding facilities located in Tennessee, Mississippi, Texas and New Jersey and provides a broad range of 2,000 SKUs and serves more than 3,000 hospital customers across all 50 states in the US.